Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vanguard I-III
- Development stage
- Unknown
- Lead developer
- Zoetis
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular
01
Overview
Vanguard I-III is a canine combination vaccine developed by Zoetis (formerly Pfizer Animal Health) designed to protect dogs against several highly contagious and potentially fatal viral diseases. It is a modified-live virus (MLV) vaccine containing attenuated strains of canine distemper virus (CDV), canine adenovirus type 2 (CAV2), and canine parainfluenza virus (CPIV). The CAV2 component provides cross-protection against canine adenovirus type 1 (CAV1), the causative agent of infectious canine hepatitis, as well as respiratory disease caused by CAV2. The vaccine is typically administered via subcutaneous or intramuscular injection to healthy dogs as part of a primary vaccination series or annual booster.
- Brand names
- Vanguard I-IIIVanguard
- Other names
- Vanguard 1-3Vanguard1-3Vanguard-1-3Canine Distemper-Adenovirus Type 2-Parainfluenza VaccineVanguard DA2P
Beyond the preview
Go deeper on Vanguard I-III.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vanguard I-III.